<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00080834</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000356034</org_study_id>
    <secondary_id>DAIICHI-927A-PRT004</secondary_id>
    <secondary_id>MDA-2003-0749</secondary_id>
    <nct_id>NCT00080834</nct_id>
  </id_info>
  <brief_title>DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma</brief_title>
  <official_title>A Phase II Study Of Oral DJ-927 Administered As A Single Dose Every Three Weeks To Patients With Advanced Or Metastatic Adenocarcinoma Of The Colon Or Rectum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as DJ-927, work in different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well DJ-927 works as second-line therapy in&#xD;
      treating patients with progressive locally advanced or metastatic colorectal adenocarcinoma&#xD;
      (cancer).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the objective tumor response rate in patients with progressive locally&#xD;
           advanced or metastatic adenocarcinoma of the colon or rectum treated with DJ-927 as&#xD;
           second-line treatment.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the duration of response in patients treated with this drug.&#xD;
&#xD;
        -  Determine the time to tumor progression in patients treated with this drug.&#xD;
&#xD;
        -  Determine the median survival time in patients treated with this drug.&#xD;
&#xD;
        -  Determine the quantitative and qualitative toxic effects of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study. Patients are stratified according to prior&#xD;
      first-line treatment regimen (irinotecan-containing vs oxaliplatin-containing).&#xD;
&#xD;
      Patients receive oral DJ-927* on day 1. Courses repeat every 21 days in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      NOTE: *Patients receive 1 of 2 selected doses to confirm the previously established maximum&#xD;
      tolerated dose&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 56-62 patients (28-31 per stratum) will be accrued for this&#xD;
      study within 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DJ-927</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the colon or rectum&#xD;
&#xD;
               -  Progressive locally advanced or metastatic disease&#xD;
&#xD;
          -  Received 1 prior irinotecan- or oxaliplatin-containing regimen&#xD;
&#xD;
          -  At least 1 measurable lesion&#xD;
&#xD;
               -  Target lesion must be outside field of prior radiotherapy&#xD;
&#xD;
          -  No symptomatic brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  ALT and AST ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases&#xD;
             are present)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No difficulty with swallowing&#xD;
&#xD;
          -  No malabsorption&#xD;
&#xD;
          -  No diarrhea (excess of 2-3 stools/day above normal frequency) within the past month&#xD;
&#xD;
          -  No history of chronic diarrhea&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No concurrent serious infection&#xD;
&#xD;
          -  No other concurrent severe or uncontrolled underlying medical condition that would&#xD;
             preclude study participation&#xD;
&#xD;
          -  No neuropathy ≥ grade 2&#xD;
&#xD;
          -  No history of any severe or life-threatening hypersensitivity reaction&#xD;
&#xD;
          -  No psychiatric disorder that would preclude study compliance&#xD;
&#xD;
          -  No other malignancy within the past 2 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior myelosuppressive chemotherapy and recovered&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
               -  Localized radiotherapy to non-indicator lesions for pain relief allowed provided&#xD;
                  other methods of pain control are ineffective&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery and recovered&#xD;
&#xD;
          -  No prior major surgery in the stomach or small intestine&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 28 days since prior investigational agents (including analgesics and/or&#xD;
             antiemetics)&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent cytotoxic therapy&#xD;
&#xD;
          -  No concurrent grapefruit products&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Cheverton, MD, ChB, MMED, RadT</last_name>
    <role>Study Chair</role>
    <affiliation>Daiichi Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of New Mexico Cancer Research and Treatment Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131-5636</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rhee JM, Lee FC, Saif MW, et al.: Phase II trial of DJ-927 as a second-line treatment for colorectal cancer demonstrates objective responses. [Abstract] J Clin Oncol 23 (Suppl 16): A-3654, 284s, 2005.</citation>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>April 7, 2004</study_first_submitted>
  <study_first_submitted_qc>April 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2004</study_first_posted>
  <last_update_submitted>May 15, 2012</last_update_submitted>
  <last_update_submitted_qc>May 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

